The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Raffetti, Elena ^a   Donato, Francesco ^a   Castelnuovo, Filippo ^b   Ladisa, Nicoletta ^c   Paraninfo, Giuseppe ^a   Di Filippo, Elisa ^d   Segala, Daniela ^e   Cologni, Giuliana ^d   Bandera, Alessandra ^f   Zacchi, Fabio ^g   Digiambenedetto, Simona ^h   Di Pietro, Massimo ⁱ   Castelli, Francesco ^a   Quiros Roldan, Eugenia ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^e S ANNA HOSPITAL   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

^g CREMONA HOSPITAL   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

HIV; Inflammatory markers; Non Hodgkin lymphoma; Prognostic score

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; GLASGOW PROGNOSTIC SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MODIFIED GLASGOW PROGNOSTIC SCORE; MORTALITY; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; NONHODGKIN LYMPHOMA; PLATELET LYMPHOCYTE RATIO; PREDICTIVE VALUE; PROGNOSIS; PROGNOSTIC INDEX; PROGNOSTIC NUTRITIONAL INDEX; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SURVIVAL RATE; THROMBOCYTE COUNT; CLINICAL TRIAL; COMPLICATION; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEUTROPHIL; NUTRITIONAL STATUS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; THROMBOCYTE;

ADULT; AREA UNDER CURVE; BIOMARKERS; BLOOD PLATELETS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFLAMMATION; LYMPHOCYTES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPHILS; NUTRITIONAL STATUS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; ROC CURVE;

EID: 84940851384     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0446-8     Document Type: Article

References (30)

1. Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, et al. Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an Italian multicenter study. PLoS One. 2014;23:9(4).
2. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96(8):2730-4.
3. Robotin MC, Law MG, Milliken S, Goldstein D, Garsia RJ, Dolan GM, et al. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Med. 2004;5(5):377-84.
4. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, et al. A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy. Ann Intern Med. 2005;143(4):265-73.
5. Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro Murillo AM, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 2009;23(15):2029-37.
6. Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med 2014 Sep 23.
7. Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol. 2005;23(33):8477-82.
8. Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Tellez MJ, et al. Prognosis of AIDS-Related Systemic Non-Hodgkin Lymphoma Treated With Chemotherapy and Highly Active Antiretroviral Therapy Depends Exclusively on Tumor-Related Factors. JAIDS. 2007;44(2):167-73.
9. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23(19):4430-8.
10. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329(14):987-94.
11. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99.
12. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149-63.
13. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-40.
14. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218-30.
15. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.
16. Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1537-49.
17. Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol. 2015;94(1):57-63.
18. Troppan K, Deutsch A, Gerger A, Stojakovic T, Beham-Schmid C, Wenzl K, et al. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer. 2014;110(2):369-74.
19. Li YJ, Jiang WQ, Huang JJ, Xia ZJ, Huang HQ, Li ZM. The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol. 2013;88(5):394-9.
20. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278-95.
21. Harrell F. General Aspects of Fitting Regression Models. In: Regression Modeling Strategies - With Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer-Verlag; 2011. p. 23-4.
22. Akaike H. A New Look at the Statistical Model Identification. IEEE Trans Autom Control. 1974;AC-19(6):716-23.
23. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-61.
24. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-42.
25. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, et al. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther. 2007;12(6):931-9.
26. Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010;24(11):1765-70.
27. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251-62.
28. Gopal S, Patel MR, Yanik EL, Cole SR, Achenbach CJ, Napravnik S, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013;105(16):1221-9.
29. Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, et al. A new prognostic score for AIDS-related lymphomas in the Rituximab-era. Haematologica. 2014;123(6):837-42.
30. Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR. Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma. 2001;41:105-16.